Tenax Therapeutics has raised about $100 million in private funding to help accelerate the clinical development of oral levosimendan…
Articles by Patricia Inácio, PhD
The U.S. Food and Drug Administration (FDA) has given orphan drug designation to ZM001, a first-in-class investigational antibody from…
Patients with an intermediate to high risk of mortality in the first year following a pulmonary arterial hypertension (PAH)…
High blood levels of resistin, a hormone produced by fat cells, may help identify pulmonary arterial hypertension…
A natural substance isolated from a houseplant shows promise as a potential treatment to prevent and reverse pulmonary hypertension…
Reviva Pharmaceuticals has been granted a patent in Europe that covers using brilaroxazine, formerly RP5063, for pulmonary hypertension…
Anumana‘s artificial intelligence (AI) algorithm shows promise for the early detection of pulmonary hypertension (PH), a study suggested.
A new study identifies the presence of bacteria from the genus Eubacterium fissicatena, known for their pro-inflammatory properties, as a…
The physical activity component of the PAH-SYMPACT — a patient-reported measure of quality of life tailored for people with…
Direct oral anticoagulants (DOACs) — a type of blood thinner medication — are as safe and effective as vitamin K…
Life support measures, specifically the need for assisted breathing, and elevated blood levels of bilirubin, a marker of liver damage,…
Tenax Therapeutics has been granted another U.S. patent for levosimendan, this one covering all three routes of administration and…